Gland Pharma Limited (NSE:GLAND)

Gland Pharma Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	67,253	64,307	56,165	56,647	36,246	44,007
Revenue Growth	17.57%	14.50%	-0.85%	56.28%	-17.64%	27.08%
Gross Profit Gross Profit Growth	39,785	37,972	31,544	31,108	17,651	21,513
Operating Income Operating Income Growth	13,020	11,906	8,721	9,715	8,844	14,000
Net Income Net Income Growth	11,288	10,273	6,985	7,725	7,810	12,117
Earnings Per Share EPS Growth	68.41	62.28	42.40	46.89	47.43	73.64
EPS Growth	46.34%	46.89%	-9.58%	-1.14%	-35.59%	16.91%

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
USA USA Growth	33,552	31,185	27,403	26,878	20,910	23,327
Europe Europe Growth	14,762	14,110	10,225	10,528	1,871	2,398
India India Growth	5,582	5,510	4,765	5,880	5,548	8,801
Rest of World (ROW) Rest of World (ROW) Growth	11,230	11,169	11,377	11,817	6,893	8,481
Canada Canada Growth	-	1,404	1,574	890.27	794.9	829.19
Australia Australia Growth	-	851.32	742.94	626.45	218.24	170.87
New Zealand New Zealand Growth	-	77.11	77.23	28.17	10.86	-
Total Total Growth	67,254	64,307	56,165	56,647	36,246	44,007

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	33,591	33,591	29,522	19,388	37,628	32,457
Total Debt Total Debt Growth	2,836	2,836	3,137	3,722	44.53	47.43
Net Cash (Debt) Net Cash Growth	30,755	30,755	26,385	15,666	37,584	32,410
Net Cash Growth	16.56%	16.56%	68.42%	-58.32%	15.96%	8.10%
Net Cash Per Share Net Cash Per Share Growth	186.40	186.45	160.15	95.10	228.22	196.97

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	10,314	9,147	9,968	3,640	7,908
Capital Expenditures CapEx Growth	-	-4,908	-3,845	-3,899	-2,209	-5,113
Free Cash Flow Free Cash Flow Growth	-	5,406	5,302	6,069	1,430	2,794
Free Cash Flow Growth	-	1.97%	-12.63%	324.27%	-48.81%	-25.71%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	59.16%	59.05%	56.16%	54.92%	48.70%	48.88%
Operating Margin	19.36%	18.52%	15.53%	17.15%	24.40%	31.81%
Pretax Margin	23.59%	22.77%	18.92%	19.99%	29.10%	36.78%
Profit Margin	16.78%	15.97%	12.44%	13.64%	21.55%	27.53%
FCF Margin	-	8.41%	9.44%	10.71%	3.95%	6.35%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Dividend Per Share Dividend Per Share Growth	20.000	20.000	18.000	20.000
Dividend Per Share Growth	11.11%	11.11%	-10.00%	-
Dividend Yield	0.70%	1.19%	1.15%	1.11%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	41.21	27.20	37.56	39.35	26.74	44.38
Forward PE	35.72	26.18	27.55	29.26	17.57	35.96
P/FCF Ratio	86.03	51.69	49.48	50.08	146.03	192.42
PS Ratio	6.92	4.35	4.67	5.37	5.76	12.22

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error